Navigation Links
Get the Leading Fucoidan Supplement on the go With LIMU ORIGINAL(TM) SHOT
Date:6/1/2010

LAKE MARY, Fla., June 1 /PRNewswire/ -- The leading daily Fucoidan supplement, LIMU ORIGINAL™, is now available in a convenient two-ounce pouch as the LIMU ORIGINAL™ SHOT.  LIMU, the recognized marketplace leader of Fucoidan-based products, launched the new packaging as a part of their brand transformation initiatives.  The company has introduced several Fucoidan products into the marketplace, focusing on the marine bioactive's antioxidant, cardiovascular, energy and weight management benefits.  

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100312/FL69564LOGO )

"Fucoidan is an incredible supernutrient with proven science that offers wholesome, complete nutrition in today's fast-paced world," said Gary J. Raser, LIMU President and CEO.  "It is our company's privilege and mission to share the rich benefits of Fucoidan, and the LIMU ORIGINAL™ SHOT pouch delivery system gives consumers a chance to enjoy the potent power of LIMU ORIGINAL™ wherever they are, every day."

According to the company, the marine bioactive Fucoidan continues to garner attention as it is used in more and more consumer health products worldwide.  LIMU developed a proprietary extract with scientists familiar with the brown seaweed, limu moui, where Fucoidan is in high concentration, along with 77 additional nutritional elements.  Ongoing studies continue to strengthen Fucoidan's position as an emerging ingredient for a range of health products within the nutritionals industry.

"Our new LIMU ORIGINAL™ SHOT pouches are yet another way for our company to educate the world about Fucoidan's powerful benefits, and we continue to bring the latest developments to the marketplace," said Raser.  The company employs a direct sales business model, allowing all consumers to make additional income selling Fucoidan-based products while efficiently increasing market penetration.  LIMU will work to advance Fucoidan information in upcoming marketing campaigns.  

About LIMU™

LIMU is an established global nutritional company solely focused on marketing the rich health benefits of marine bioactive, Fucoidan.  Employing a direct sales business model, LIMU continues to expand its network of Members across the globe, with tens of millions of dollars in commissions paid. Based in Florida, LIMU is an industry leading home-based business opportunity, helping people to enjoy a higher quality of life. For more information on LIMU and its exclusive Fucoidan product formulas, please visit www.thelimucompany.com.


'/>"/>
SOURCE LIMU
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
5. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection
8. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
9. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
10. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Limited, ( ASX: ITD ), an innovative diversified healthcare company, is ... December 2016 compared with the previous corresponding period. A full "Results ... . Highlights Profit after ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; up ... 11%) Profit before tax of $2.12m (Dec 2015: ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Menopause ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... questions: What are the key drugs marketed ... Global Menopause market? What are the unit prices and ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... which specializes in thought leadership , media relations, social media, content marketing ... that will be powered through Act-On, an intuitive marketing automation platform. , Rosica ...
(Date:2/23/2017)... Boston, MA (PRWEB) , ... February 23, 2017 ... ... Education and Department of Justice jointly issued a letter to withdraw ... in accordance with their gender identity. The guidance issued in May 2016 by ...
(Date:2/23/2017)... Hill, NC (PRWEB) , ... February 23, 2017 , ... ... Platinum Sponsor for ACPA’s 74th Annual Meeting. KLS is a longtime supporter of ... 2017 as an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an approved content provider for the National Institute for Health and Care ... social care-related organizations in the National Health Service (NHS) to search, order and ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... and uncertainty in clinical trials, today announced that Premier Research, a leading clinical ... solution. , Clinical trials are becoming increasingly complex, due in part to an ...
Breaking Medicine News(10 mins):